U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H36F6N6O2
Molecular Weight 638.647
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EVACETRAPIB

SMILES

CN1N=NC(=N1)N(CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)[C@H]3CCCN(C[C@H]4CC[C@@H](CC4)C(O)=O)C5=C3C=C(C)C=C5C

InChI

InChIKey=IHIUGIVXARLYHP-YBXDKENTSA-N
InChI=1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20-,22-,26-/m0/s1

HIDE SMILES / InChI

Description

Evacetrapib (LY2484595) is a novel benzazepine-based CETP inhibitor that has been developed at Lilly Research Laboratories. Evacetrapib inhibits CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3. On 01 Sep 2016 Eli Lilly terminates the phase III ACCENTUATE trial in Hyperlipidaemia (Adjunctive treatment) in USA and Puerto Rico (PO) due to insufficient efficacy (NCT02227784).

Originator

Eli Lilly
239

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
Cholesteryl ester transfer protein
15
Inhibitor
8,504
 5.5 nM [IC50]
Cytochrome P450 2C9
50
Inhibitor
8,504
 0.57 µM [Ki]
Cytochrome P450 3A4
127
Inhibitor
8,504
 1.2 µM [Ki]
Cytochrome P450 2D6
62
Inhibitor
8,504
 2.1 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Hypercholesterolemia
51
 Primary
Phase III
665
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
377 ng/mL
100 mg 1 times / day steady-state, oral
 EVACETRAPIB plasma
Homo sapiens
1142 ng/mL
130 mg single, oral
 EVACETRAPIB plasma
Homo sapiens
1330 ng/mL
600 mg 1 times / day steady-state, oral
 EVACETRAPIB plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
4610 ng × h/mL
100 mg 1 times / day steady-state, oral
 EVACETRAPIB plasma
Homo sapiens
16320 ng × h/mL
130 mg single, oral
 EVACETRAPIB plasma
Homo sapiens
13700 ng × h/mL
600 mg 1 times / day steady-state, oral
 EVACETRAPIB plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
44 h
100 mg 1 times / day steady-state, oral
 EVACETRAPIB plasma
Homo sapiens
52.8 h
130 mg single, oral
 EVACETRAPIB plasma
Homo sapiens
37.4 h
600 mg 1 times / day steady-state, oral
 EVACETRAPIB plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
2.4%
130 mg single, oral
 EVACETRAPIB plasma
Homo sapiens

Doses

AEs

PubMed

Patents

08299060
2
08329688
2
20100331309
2
20120058990
2
8299060
2
8329688
2

Sample Use Guides

In Vivo Use Guide
Evacetrapib 130 mg tablet, administered orally once , daily for up to 4 years.
Route of Administration: Oral
In Vitro Use Guide
Evacetrapib inhibited human recombinant CETP protein (5.5 nM IC(50)) and CETP activity in human plasma (36 nM IC(50)) in vitro.
ACTIVE MOIETY
Structure of EVACETRAPIB
SALT/SOLVATE (PARENT)
Structure of EVACETRAPIB MONOHYDRATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966